University of Alabama at Birmingham (UAB) Pediatric CBD Program
Status:
Completed
Trial end date:
2019-02-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various
doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating
debilitating, drug-resistant epilepsy.